Atsuko Mokubo Selected Research

Glucose (Dextrose)

1/2020	Canagliflozin Increases Calorie Intake in Type 2 Diabetes Without Changing the Energy Ratio of the Three Macronutrients: CANA-K Study.
1/2019	Renal effects of sodium glucose co-transporter 2 inhibitors in Japanese type 2 diabetes mellitus patients with home blood pressure monitoring.
1/2019	Retrospective analysis of effects of sodium-glucose co-transporter 2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease.
2/2016	Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.
7/2015	Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Atsuko Mokubo Research Topics

Disease

19	Type 2 Diabetes Mellitus (MODY) 10/2023 - 07/2006
9	Body Weight (Weight, Body) 12/2021 - 04/2014
4	Chronic Renal Insufficiency 10/2023 - 01/2019
2	Weight Loss (Weight Reduction) 01/2020 - 02/2016
2	Hypothyroidism 01/2017 - 01/2011
2	Autoimmune Hypophysitis 01/2017 - 01/2014
2	Hypoglycemia (Reactive Hypoglycemia) 07/2015 - 12/2012
1	Kidney Diseases (Kidney Disease) 09/2020
1	Glycosuria 01/2020
1	Masked Hypertension 01/2019
1	Hypertension (High Blood Pressure) 01/2019
1	White Coat Hypertension 01/2019
1	Insulin Resistance 05/2016
1	Obesity 05/2016
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2014
1	Autoimmune Diseases (Autoimmune Disease) 01/2014
1	Diabetic Nephropathies (Diabetic Nephropathy) 07/2006
1	Hypertrophy 12/2003
1	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 12/2003
1	Cardiomyopathies (Cardiomyopathy) 12/2003

Drug/Important Bio-Agent (IBA)

7	Sitagliptin Phosphate (Januvia)FDA Link 03/2020 - 10/2012
6	ipragliflozinIBA 09/2020 - 02/2016
6	Hemoglobins (Hemoglobin)IBA 03/2020 - 07/2015
5	Sodium-Glucose Transporter 2 InhibitorsIBA 12/2021 - 05/2016
5	Insulin (Novolin)FDA Link 03/2020 - 03/2014
5	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 07/2015
4	SodiumIBA 01/2020 - 02/2016
3	Sodium-Glucose Transport ProteinsIBA 10/2023 - 01/2019
3	SymportersIBA 01/2019 - 02/2016
2	CanagliflozinIBA 12/2021 - 01/2020
2	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 05/2019 - 05/2016
2	Thyrotropin (Thyroid-Stimulating Hormone)FDA Link 01/2017 - 01/2011
2	Growth Hormone (Somatotropin)IBA 01/2017 - 01/2011
2	ProlactinIBA 01/2017 - 01/2011
2	Blood Glucose (Blood Sugar)IBA 04/2014 - 10/2012
1	LipidsIBA 07/2017
1	Transcription Factor Pit-1 (Transcription Factor Pit 1)IBA 01/2017
1	Hypoglycemic Agents (Hypoglycemics)IBA 05/2016
1	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 07/2015
1	CreatinineIBA 07/2015
1	Liraglutide FDA Link 04/2014
1	Glucagon-Like Peptide-1 ReceptorIBA 04/2014
1	N-Acetylneuraminic Acid (Sialic Acid)IBA 01/2014
1	AutoantibodiesIBA 01/2014
1	AcetylesteraseIBA 01/2014
1	Proteins (Proteins, Gene)FDA Link 01/2011
1	ChemokinesIBA 07/2006
1	Chemokine ReceptorsIBA 07/2006
1	Chemokine CCL5IBA 07/2006
1	Mitochondrial DNA (mtDNA)IBA 12/2003

Therapy/Procedure

7	Therapeutics 12/2021 - 12/2012
6	Glycemic Control 03/2020 - 07/2015
1	Exercise Therapy (Therapy, Exercise) 05/2016